Synergy Innovation Co. Ltd.
KKRX:0488701,414.00
KRW
-62.00
(-4.20%)
ISIN
KR7048870000
Return %
Stock
S&P 500
1Y
-43.67
14.20
3Y
-48.68
81.12
5Y
-65.13
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jin-Hyeong Park
- Full Time Employees
- 65
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seongnam-si South Korea
- IPO Date
- Aug 13, 2004
- Website
- synergyinno.com
- Similar Companies
- Business
- Synergy Innovation Co., Ltd. is a South Korea-based healthcare and biotechnology management company primarily engaged in the research, development, manufacturing, and distribution of microbiological culture media, in vitro diagnostic transport systems, interventional medical devices, and finished pharmaceuticals. Founded in April 1998 as Core Logic Co., Ltd. and headquartered in Seongnam-si, Gyeonggi-do, Republic of Korea, the company transitioned into a life sciences and bio-management platform following its 2017 merger with KOMED Bio Science Co., Ltd. and subsequent corporate rebranding. Synergy Innovation operates across three principal business segments: Medical Devices and In Vitro Diagnostics, Pharmaceuticals, and Health Functional Foods. Its comprehensive product and service portfolio comprises: prepared culture media (PPM), including blood agar plates, MacConkey agar, and chromogenic media engineered for clinical microbiology, pharmaceutical cleanroom monitoring, food hygiene inspection, and cosmetic quality assurance; liquid broth media, antibiotic susceptibility testing reagents, and automated media dispensation solutions; specimen collection and transport systems, headlined by the proprietary SI-UTS (Universal Transport Solution) for preserving and transporting viral and bacterial clinical specimens; interventional medical devices, including self-expanding metallic non-vascular and vascular stents developed via specialized affiliates; ethical and generic pharmaceutical formulations, active pharmaceutical ingredients, and contract manufacturing services; and dietary nutritional supplements. The company supplies clinical laboratories, general hospitals, pharmaceutical producers, and research institutions domestically across South Korea as well as international markets in Asia, Europe, and the Americas. In recent corporate and operational developments, Synergy Innovation transitioned to a sole leadership structure under Chief Executive Officer Jin-Hyung Park in March 2024 following the resignation of its co-CEO. Over the recent operating period, the company executed major governance restructuring initiatives involving the transfer of its controlling equity interest to the S-Innovation New Technology Fund, while actively streamlining non-core assets. Concurrently, Synergy Innovation expanded its bio-industrial footprint by securing majority and controlling equity stakes in pharmaceutical producer Medica Korea Co., Ltd. and medical device manufacturer S&G Biotech Inc. (Vasnova), while advancing strategic joint research initiatives, including specialized cell culture media localization projects with the Korea Advanced Institute of Science and Technology (KAIST) and targeted equity investments in next-generation RNA-based therapeutics developer Rznomics Co., Ltd.